Roivant Sciences Ltd. (ROIV)
| Market Cap | 19.93B |
| Revenue (ttm) | 13.31M |
| Net Income (ttm) | -809.24M |
| Shares Out | 715.70M |
| EPS (ttm) | -1.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,387,958 |
| Open | 27.33 |
| Previous Close | 28.10 |
| Day's Range | 26.94 - 28.24 |
| 52-Week Range | 8.73 - 29.20 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 27.44 (-1.47%) |
| Earnings Date | Feb 6, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $27.44, which is a decrease of -1.47% from the latest price.
News
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first...
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV...
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a high...
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reporte...
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, Feb...
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update
The Goldman Sachs Mid Cap Growth Fund underperformed its benchmark, the Russell Midcap Growth Index (net), during the quarter. United Rentals, Inc. released a positive quarterly earnings report, surpa...
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day
BASEL, Switzerland and LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline u...
Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript
Roivant Sciences Ltd. ( ROIV) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding -...
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced
ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease dru...
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Roivant Sciences Ltd. ( ROIV) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST Company Participants Richard Pulik - Chief Financial Officer Conference C...
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences Ltd. ( ROIV) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Direc...
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided ...
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business ...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Nov...
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I...
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants J...
Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference ...